MBX BIOSCIENCES TO PROVIDE 2026 OUTLOOK AND BUSINESS UPDATE AT 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
MBX BIOSCIENCES INC - PHASE 3 TRIAL OF CANVUPARATIDE TO START IN Q3 2026
MBX BIOSCIENCES INC - PHASE 1 DATA FOR MBX 4291 EXPECTED IN Q4 2026
MBX BIOSCIENCES INC - TWO NEW OBESITY CANDIDATES TO BE NOMINATED IN 2026
Source text: ID:nGNX6CLC51
Further company coverage: MBX.O
((Reuters.briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.